ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most ...
Updated full-year 2026 revenue guidance to $690 million to $710 million, assuming continued GBM momentum and initial ...
It’s one of the most lethal cancers, and it affects about 20,000 Americans a year. Glioblastoma is an aggressive, fast-growing brain tumor. While there are treatments for glioblastoma, there is no ...
Investor's Business Daily on MSN
Two medical stocks skyrocket after demolishing views — and one is about to break out
Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter ...
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of ...
The decision was supported by results from the PANOVA‑3 Phase 3 trial, which compared Optune Pax plus chemotherapy against chemotherapy alone in 571 patients. The combination delivered a median ...
LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...
Novocure recently announced final results from a phase III EF-14 clinical trial of its Optune device for treatment of newly diagnosed glioblastoma (GBM). According to Novocure’s press release, the ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
CHAPEL HILL, N.C -- It's one of the most lethal cancers, and it affects about 20,000 Americans a year. Glioblastoma is an aggressive, fast-growing brain tumor. While there are treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results